KDNY — Chinook Therapeutics Share News
0.000.00%
Last trade - 00:00- $2.90bn
- $2.60bn
- $6.13m
Chinook Therapeutics Inc expected to post a loss of 67 cents a share - Earnings Preview
Chinook up as dosing starts in kidney disorder drug trial
Brief: Chinook Therapeutics Reports Initiation Of Phase 1 Trial Of CHK-336
Brief: Chinook Therapeutics Reports Q4 And FY 2021 Financial Results
Brief: Chinook Therapeutics Appoints Charlotte Jones-Burton As Senior Vice President Of Product Development And Strategy
Brief: Chinook Therapeutics Receives Orphan Drug Designation From European Commission For Atrasentan For Treatment Of Primary IgA Nephropathy
Brief: Chinook Therapeutics As Consideration For Rights Granted To Sanreno Under License Agreement
Brief: Chinook Therapeutics Announces Formation Of Sanreno Therapeutics, A Joint Venture To Develop Kidney Disease Therapies In China
Brief: Chinook Therapeutics Pricing Of Its Upsized Underwritten Public Offering Of 7.8 Million Shares At A Price To Public Of $14.00 Per Share
Chinook Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Chinook Therapeutics Announces Proposed Public Offering Of Common Stock
Brief: Chinook Therapeutics Reports Qtrly Loss Per Share Of $0.69
Chinook Therapeutics Inc expected to post a loss of 84 cents a share - Earnings Preview
Chinook Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Chinook Therapeutics Provides Business Update And Reports Q2 Results
Chinook Therapeutics Inc expected to post a loss of 78 cents a share - Earnings Preview
Chinook Therapeutics Inc expected to post a loss of 78 cents a share - Earnings Preview
Chinook Therapeutics Inc expected to post a loss of 78 cents a share - Earnings Preview
Chinook Therapeutics Inc expected to post a loss of 78 cents a share - Earnings Preview